Researchers at Stanford have developed a combination therapy to treat neuroblastoma, the most common and deadly solid tumor in childhood. Neuroblastoma derives from neural crest cells that fail to exit the cell cycle and differentiate.
Researchers at Stanford have developed methods of using CRISPR/Cas9-mediated genome editing to treat patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Approximately 85% of lung cancers are NSCLC.
Researchers at Stanford have developed a new, patented strategy to enhance anti-tumor immune responses to treat cancer. Cancer is the second leading cause of death in the United States and inflicts a tremendous burden on public health.
Researchers at Stanford have developed a method to direct T cell fate toward the T stem cell memory (TSCM) phenotype during ex vivo expansion for adoptive cell transfer (ACT) therapies.
Researchers at Stanford and their colleagues have developed easily expressed Wnt agonist and antagonists. Wnts are central mediators of development as they influence cell proliferation, differentiation and migration.
Researchers at Stanford have engineered proteins to selectively sensitize T cells to IL-2. The ability to manipulate immune cells for therapeutic use is of great clinical interest. Cytokines are signaling molecules that can be used to alter cellular behavior.
Researchers at Stanford have developed methods to classify and treat MYC-driven hematopoietic cancers. The MYC oncogene drives the proliferation and survival of many hematopoietic cancers. These cancers are highly aggressive and do not respond to conventional chemotherapies.
Researchers in Prof. Gerald Crabtree's laboratory have developed a method for identifying cancer patients that are likely to benefit from treatment with topoisomerase IIa (TOP2A) inhibitors.
Researchers in Prof. Gerald Crabtree's laboratory have identified the pathological mechanism for synovial sarcoma (SS) that could be used to develop targeted therapeutics. This approach aims to reverse the effects of the SS18-SSX fusion protein (the hallmark of human SS).
Researchers in Dr. Michelle Monje-Deisseroth's lab at Stanford have recently identified therapeutic targets for drug development to limit the spread of high-grade gliomas (HGGs).
Researchers in Dr. James Chen's lab at Stanford have discovered novel Hedgehog (Hh) pathway inhibitors that may serve as anti-cancer therapeutics. The Hh pathway plays a critical role in patterning, homeostasis, and oncogenic transformation of multiple tissues.
Stanford researchers have developed a method that can tune the ratio between reversible (RE) and irreversible (IRE) electroporation through waveform adjustments.
Stanford researchers have proposed antibody-based reduction of Neuromedin (NMU) signaling as a therapeutic strategy to improve glucose metabolism in multiple physiological or disease states, including obesity, diabetes, and cancer where NMU levels are elevated.